Cargando…
Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distre...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768928/ https://www.ncbi.nlm.nih.gov/pubmed/33392443 http://dx.doi.org/10.1093/jncics/pkaa067 |
_version_ | 1783629234284003328 |
---|---|
author | Sedhom, Ramy Ferrell, Betty Ruel, Nora Koczywas, Marianna Chung, Vincent Smith, Thomas J |
author_facet | Sedhom, Ramy Ferrell, Betty Ruel, Nora Koczywas, Marianna Chung, Vincent Smith, Thomas J |
author_sort | Sedhom, Ramy |
collection | PubMed |
description | BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distress. We used data from a randomized trial testing a palliative care support intervention for patients enrolled on phase I trials. METHODS: Patients (n = 479) were accrued to the parent study prior to initiating a phase I clinical trial with data collected at baseline, 4, and 12 weeks. We determined the correlation of PRO-CTCAE with distress level, Functional Assessment of Cancer Therapy - General (FACT-G) total, and subscale domain scores. RESULTS: Patients were predominantly female (56.8%) and older than age 60 years, and 30.7% were from minority populations. The correlation coefficient for distress level for all PRO-CTCAE items was small to moderate (Pearson r = 0.33-0.46). Pearson correlation coefficient for FACT-G total was moderate (r = -0.45 to -0.69). Stronger associations were noted for mood items of the PRO-CTCAE only (with distress level, r = 0.55-0.6; with FACT-G, r = -0.54 to -0.6). PRO-CTCAE symptom interference scores had the strongest correlation with distress level (Pearson r = 0.46) and FACT-G total (Pearson r = -0.69). Correlations between PRO-CTCAE items and corresponding FACT-G (total and subscales) and distress levels reached statistical significance for all items (P <.001). CONCLUSION: Evidence demonstrates validity of PRO-CTCAE in a heterogeneous US sample of patients undergoing cancer treatment on phase I trials, with small to moderate correlations with distress level for all PRO-CTCAE items and moderate correlations with quality of life as measured by FACT-G total. |
format | Online Article Text |
id | pubmed-7768928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77689282020-12-31 Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials Sedhom, Ramy Ferrell, Betty Ruel, Nora Koczywas, Marianna Chung, Vincent Smith, Thomas J JNCI Cancer Spectr Article BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distress. We used data from a randomized trial testing a palliative care support intervention for patients enrolled on phase I trials. METHODS: Patients (n = 479) were accrued to the parent study prior to initiating a phase I clinical trial with data collected at baseline, 4, and 12 weeks. We determined the correlation of PRO-CTCAE with distress level, Functional Assessment of Cancer Therapy - General (FACT-G) total, and subscale domain scores. RESULTS: Patients were predominantly female (56.8%) and older than age 60 years, and 30.7% were from minority populations. The correlation coefficient for distress level for all PRO-CTCAE items was small to moderate (Pearson r = 0.33-0.46). Pearson correlation coefficient for FACT-G total was moderate (r = -0.45 to -0.69). Stronger associations were noted for mood items of the PRO-CTCAE only (with distress level, r = 0.55-0.6; with FACT-G, r = -0.54 to -0.6). PRO-CTCAE symptom interference scores had the strongest correlation with distress level (Pearson r = 0.46) and FACT-G total (Pearson r = -0.69). Correlations between PRO-CTCAE items and corresponding FACT-G (total and subscales) and distress levels reached statistical significance for all items (P <.001). CONCLUSION: Evidence demonstrates validity of PRO-CTCAE in a heterogeneous US sample of patients undergoing cancer treatment on phase I trials, with small to moderate correlations with distress level for all PRO-CTCAE items and moderate correlations with quality of life as measured by FACT-G total. Oxford University Press 2020-08-14 /pmc/articles/PMC7768928/ /pubmed/33392443 http://dx.doi.org/10.1093/jncics/pkaa067 Text en © The Author(s) 2020. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Sedhom, Ramy Ferrell, Betty Ruel, Nora Koczywas, Marianna Chung, Vincent Smith, Thomas J Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials |
title | Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials |
title_full | Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials |
title_fullStr | Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials |
title_full_unstemmed | Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials |
title_short | Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials |
title_sort | using patient-reported outcomes to describe the patient experience on phase i clinical trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768928/ https://www.ncbi.nlm.nih.gov/pubmed/33392443 http://dx.doi.org/10.1093/jncics/pkaa067 |
work_keys_str_mv | AT sedhomramy usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials AT ferrellbetty usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials AT ruelnora usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials AT koczywasmarianna usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials AT chungvincent usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials AT smiththomasj usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials |